PMID

Data

Article Title

Organization

Thalidomide analogs and PDE4 inhibition.

Celgene

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.

Celgene

Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223.

Celgene

Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.

Celgene

Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.

Celgene

Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury.

Celgene

Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.

Celgene

Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.

Celgene

Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.

Celgene

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.

Celgene

Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.

Celgene

Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.

Celgene

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity.

Celgene

1,1-Diarylalkenes as anticancer agents: dual inhibitors of tubulin polymerization and phosphodiesterase 4.

Celgene

Structure-based design and discovery of potent and selective KDM5 inhibitors.

Celgene

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.

Celgene

Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8).

Celgene

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.

Celgene

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.

Celgene